On April 8, 2022 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will present additional positive immunogenicity and clinical data on TG4050, its individualized neoantigen cancer vaccine (Press release, Transgene, APR 8, 2022, View Source [SID1234611721]). TG4050 is currently being evaluated in two ongoing multicenter Phase I trials in patients with ovarian cancer and head and neck cancer. In a poster presentation, Transgene will discuss how these new data further demonstrate the ability of this neoantigen cancer vaccine to induce strong immune responses, targeting patient-specific mutations, that are expected to translate into clinical benefit for patients.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These results will be presented during a late-breaking poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) meeting on April 12, 2022, in New Orleans, Louisiana, USA.
New immune cell response data confirm the ability of this individualized vaccine to effectively prime the immune system
Transgene is presenting a comprehensive set of immunological data. Circulating immune cells quantification (in particular monocytes, DC, NK cells, subcells of CD8, CD4, Treg) and expression of immune checkpoints (ICOS and PD1) suggest that the vaccine is able to effectively induce innate and adaptive immune responses in patients.
All evaluable patients developed a robust T-cell responses against multiple targeted neoantigens (median of 10 positive responses per patient). T-cell responses were observed for class I and class II epitopes, they consisted of de novo responses and amplifications of preexisting responses.
New clinical data obtained from patients treated with TG4050 provide a positive update on the two ongoing trials
In the head and neck trial, patients have been randomized to immediatly receive vaccination with TG4050 (early treatment arm, arm A) or at relapse (delayed vaccination arm, arm B). All patients randomized to arm A (n=7) are stable as of mid-March 2022. In arm B (n=6), two patients have recently experienced relapse.
In the ovarian trial (n=4), one patient treated after an elevation of CA-125 experienced a normalization of CA-125 without clinical progression for 9 months until death from an unrelated chronic illness. Another patient was treated upon onset of radiological evidence of relapse and was stable for 11.4 months.
To date, the vaccine has been well tolerated and no related Serious Adverse Events have been reported across the two studies.
In both clinical studies, enrollment and patient dosing are progressing in line with our expectations. Overall, Transgene plans to treat 13 patients in the ovarian cancer trial and 30 patients in the head and neck trial.
Poster title: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
·Session title: Phase I Clinical Trials 2
· Poster and abstract number: CT182
· Date, time, location: Tuesday, April 12, 2022, 9:00 AM – 12:30 PM CDT, Board 7, Section 33
· Authors: M. Block, JP Delord, C. Ottensmeier, C. Le Tourneau, A. Lalanne, O. Lantz, K. Knutson, G. Lacoste, A. Tavernaro, M. Brandely, N. Silvestre, B. Grellier, Y. Yamashita, O. Kousuke, N. Yamagata, E. Quemeneur, K. Bendjama
The abstract and the poster can be accessed on the AACR (Free AACR Whitepaper) and Transgene websites.
First positive preliminary clinical data generated in the first patients treated with TG4050 were announced in November 2021 and can be found here.
Transgene is also presenting preclinical data obtained with BT-001 at the AACR (Free AACR Whitepaper) meeting. BT-001 is an Invir.IO based oncolytic virus, encoding a Treg-depleting human recombinant anti-CTLA-4 antibody generated by BioInvent and the human GM-CSF cytokine.
Poster title: "Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg‑depleting @CTLA4 and GM-CSF"
Poster and abstract number: 3567
More information can be found here.
The abstract and the poster can be accessed on the AACR (Free AACR Whitepaper) and Transgene websites.
About the clinical trials
TG4050 is being evaluated in two Phase I clinical trials for patients with ovarian cancer (NCT03839524) and HPV-negative head and neck cancers (NCT04183166).
In a first Phase I trial, TG4050 is being administered to patients with HPV-negative head and neck cancer. A personalized treatment is created for each patient after they complete surgery and while they receive an adjuvant therapy. Half of the participants receive their vaccine immediately after they complete their adjuvant treatment. The other half is given TG4050 as an additional treatment at the time of recurrence of the disease. This randomized study is evaluating the treatment benefits of TG4050 in patients who have a high risk of relapse. Up to 30 patients will receive TG4050 in France, in the UK and in the USA. The principal investigator of the trial is Prof. Christian Ottensmeier, MD, PhD, Consultant Medical Oncologist at the Clatterbridge Cancer Centre and Professor of Immuno-Oncology at the University of Liverpool. In France, the clinical trial is being conducted at Institut Curie, Paris by Prof. Christophe Le Tourneau, MD, PhD, Head of the Department of Drug Development and Innovation (D3i), and at the IUCT-Oncopole, Toulouse by Prof. Jean-Pierre Delord. In the USA, the trial is being led by Dr. Yujie Zhao, MD, PhD, at the Mayo Clinic. Endpoints of the trial include safety, feasibility and biological activity of the therapeutic vaccine.
In parallel, a Phase I clinical trial of TG4050 is enrolling patients with ovarian cancer. This second trial is including patients at the time of asymptomatic relapse after surgery and first-line chemotherapy. Dr. Matthew Block, MD, PhD, Consultant Medical Oncology, Consultant Immunology and Associate Professor of Oncology at the Mayo Clinic (USA) is the principal investigator of the trial; in France, the trial is being conducted by Prof. Le Tourneau, MD, PhD, at Institut Curie and by Dr. Alexandra Martinez, MD, Associate Head of Surgical Department, at IUCT-Oncopole. Endpoints of the trial include safety, feasibility and biological activity of the therapeutic vaccine.
First positive preliminary clinical data generated in the first patients treated with TG4050 were announced in November 2021. More information here or in this video here.
About myvac
myvac is a viral vector (MVA – Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac-derived products are designed to stimulate the patient’s immune system, recognize and destroy tumors using the patient’s own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded "Investment for the Future" funding from Bpifrance for the development of its platform myvac. TG4050 is the first myvac-derived product being evaluated in clinical trials.
About TG4050
TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac technology and powered by NEC’s longstanding artificial intelligence (AI) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC’s Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences.
TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed and produced for each patient.